Objective and design Azithromycin (AZM) has been used as an anti-inflammatory agent in the treatment of cystic fibrosis (CF), particularly those with chronic infection with P. aeruginosa (PA). To investigate mechanisms associated with the beneficial effects of AZM in CF, we examined bacterial load, cytokine levels, and clearance of inflammatory cells in CF mice infected with mucoid PA and treated with AZM. Methods Gut-corrected Cftr tm1Unc -TgN(FABPCFTR)#Jaw CF mice infected with an alginate-overproducing PA CFisolate were treated with AZM or saline and examined for survival of animals, lung bacterial load, inflammation, cytokine levels, and apoptotic cells up to 5 days post-infection. Results Administration of AZM (20 mg/kg) 24 h after the infection improved 5-day survival to 95% compared with treatment with saline (56%). AZM administration was associated with significant reductions in bacterial load, decreased lung inflammation, and increased levels of IFN-c. AZM increased macrophage clearance of apoptotic neutrophils from the lung.
Introduction
The inflammatory response in cystic fibrosis (CF) is characterized by the excess expression of inflammatory cytokines coupled with chronic endobronchial neutrophilia, leading to bronchiectasis and a progressive decline in pulmonary function [1] . Pseudomonas aeruginosa (PA) causes persistent infection in CF patients. The ability of this organism to convert into a mucoid phenotype and form biofilm is an important feature in the pathogenesis of lung disease in CF patients. Mucoid PA (MPA) resists detection and phagocytosis by immune cells [2] [3] [4] and has increased tolerance to antibiotics [5] . PA also impairs neutrophil bactericidal function, accelerates neutrophil death and inhibits the clearance of apoptotic neutrophils by macrophages [6] . This results in decreased pool of viable neutrophils that can phagocytose and kill bacteria. The release of elastase from necrotic neutrophils can cause further tissue damage and recruit more neutrophils to airways [6, 7] .
Macrolides have been used successfully in the treatment of diffuse pan-bronchiolitis, a lung condition associated with chronic endobronchial infection with PA and other bacteria. Macrolide therapy significantly improves lung function in CF patients [8, 9] . In azithromycin (AZM) clinical trials, CF patients receiving AZM showed improved viscoelasticity of sputum [10] , decreased sputum PA load, fewer pulmonary exacerbations and improved lung function [11] [12] [13] . However, the precise mechanisms by which AZM improves pulmonary status in patients with CF are unclear.
In vitro studies demonstrate that macrolides modulate proinflammatory responses from bronchial epithelial cells and macrophage function. Clarithromycin suppresses early phase IL-8 production from normal airway epithelial cells in response to PA flagella [14] . AZM selectively reduces TNF-a expression in CF airway epithelial cells [15] . AZM treatment increases the phagocytosis of apoptotic cells by macrophages, implying that this macrolide may augment clearance of apoptotic cells from the lung [16] . In addition to these anti-inflammatory effects, AZM inhibits transcription of PA genes responsible for quorum-sensing, which in turn controls biofilm formation and regulation of virulence factors [17] . AZM also inhibits assembly of type IV pili, thus restricting twitching motility required for biofilm formation, and increasing susceptibility of bacteria to phagocytosis [18] .
Macrolide therapy decreases bronchoalveolar lavage (BAL) neutrophils in patients with chronic airways disease with PA infection [19] . Using a mouse model of chronic endobronchial PA infection, we have found that treatment with AZM attenuates neutrophil recruitment in the lung [20] . Macrolide treatment of mice chronically infected with PA also normalizes lymphocyte counts and CD4?/CD8? ratio, while reducing lung levels of IL-1b, IL-2, IL-4, IL-5, IFN-c, and TNF-a [21, 22] . Recently, AZM was shown to reduce spontaneous and LPS-induced acute inflammation in CF mice [23] and decrease bacterial load, neutrophil infiltration and lung pathology in PA-infected, gut-corrected CF mice by blocking quorum-sensing and biofilm formation [24] . The latter study employed a novel model of chronic endobronchial infection in which mice are infected with PA suspended in alginate [25] . This model offers an advantage over previous endobronchial infection models, which employ agarose beads to harbor bacteria, thereby preventing the clearance of PA from the airways. In the present study, we used this model of PA infection to examine the effect of AZM on the pulmonary inflammatory response in CF mice. We hypothesized that AZM attenuates the inflammatory response to MPA infection in CF mice by augmenting the clearance of bacteria and infiltrating neutrophils from the lungs.
Materials and methods
Bacteria and growth conditions NH57388A, a stable MPA isolate from a CF patient, was kindly provided by Dr. N. Hoffman (University of Copenhagen, Denmark) [25] . Bacteria were maintained as a glycerol stock at -80°C and subcultured on Pseudomonas isolation agar (Difco Laboratories, Detroit, MI). For infection, bacteria were grown in tryptic soy broth overnight, harvested by centrifugation and finally suspended in purified alginate to a required concentration based on OD 600 (1 O.D. unit is equivalent to 1 9 10 9 CFU/ml). The actual concentration of bacteria in a suspension was determined by plating.
Isolation and purification of alginate P. aeruginosa alginate was isolated as described previously [26, 27] with some modifications. Briefly, the MPA isolate NH57388A was grown in 200 ml of Pseudomonas isolation media containing 1% glycerol for 36 h. Culture supernatant was harvested by centrifugation at 25,000g for 30 min at 4°C and incubated at 80°C for 30 min. Alginate was precipitated by adding three volumes of ethanol, spooled with a sterile glass rod, washed three times with alcohol and dried under a vacuum. Alginate was dissolved in sterile PBS at 5 mg/ml, treated with proteinase K for 4 h at 56°C, and incubated at 80°C for 30 min to inactivate the enzyme. Alginate was precipitated and washed again with ethanol as described above and lyophilized. This partially purified alginate was redissolved in sterile PBS to 3 mg/ml by dry weight. For infection of mice, bacteria were suspended in 1 mg/ml alginate.
Animals
Ten to twelve week-old female homozygous CF mice, strain Cftr tm1/Unc -TgN(FABPCFTR)Jaw/J, were purchased from Case Western Reserve University Animal Resource Center (Cleveland, OH). Mice were maintained in a specific-pathogen free barrier facility in microisolator cages throughout the experiment. Mice were acclimatized for 2-3 weeks before infection. All procedures were approved by the Animal Ethics Committee of the University of Michigan.
Infection and treatment of animals
Mice were anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (1 mg/kg) and infected with 50 ll of alginate alone (sham) or alginate containing MPA (5 9 10 6 CFU) by the intratracheal route. After 24 h, MPA-infected animals were treated with 100 ll of saline or saline containing AZM (20 mg/kg). The AZM dose was chosen based on our previous pharmacokinetics study, which showed plasma concentration of AZM equivalent to that found in humans treated with AZM [20] . Mice were killed at 3 or 5 days post-infection by intraperitoneal injection of 0.3 ml of 30% pentobarbital. Lung homogenates from seven to nine mice per group were used to determine lung bacterial load, myeloperoxidase activity, and cytokine levels. BAL fluid was obtained from five animals per group. Lungs from three mice per group were processed for histology.
Lung bacterial load
Lungs were harvested aseptically and homogenized in sterile PBS. A tenfold serial dilution of lung homogenates was plated on Pseudomonas isolation agar.
Analysis of lung cytokines and myeloperoxidase activity
Lung homogenates were prepared in the presence of protease inhibitors and centrifuged. Supernatant cytokines were analyzed by bioplex immune assay (BioRad, Hercules, CA). Lung myeloperoxidase activity was quantified by a method described previously [28] .
Bronchoalveolar lavage (BAL)
Total and differential cell counts in BAL were determined by staining cytospins with Diff Quick (Dade Behring, Newark, DE), as described previously [29, 30] .
Histopathology
Lungs were inflation fixed via the trachea with 10% formalin overnight and embedded in paraffin. Lung sections (5 lm thick) were stained with hematoxylin and eosin or periodic-acid Schiff's reagent.
Apoptotic cells in lungs
Paraffin sections of lungs were deparaffinized, rehydrated and stained for apoptotic cells by using a DeadEnd Fluorometric TUNEL assay kit (Promega, Madison, WI) following the manufacturer's instructions. Briefly, sections were treated with proteinase K to permeabilize the cells, and the fragmented DNA in apoptotic cells was labeled by catalytically incorporating fluorescein-12-dUTP at the 3 0 -hydroxyl ends of fragmented DNA using the enzyme terminal deoxynucleotidyl transferase. Sections were counterstained with DAPI nuclear stain. The fluorescein-dUTP-labeled DNA was then visualized by confocal microscopy. To quantify the phagocytic capacity of macrophages, BAL cells were stained with DeadEnd Fluorometric TUNEL assay as above. Apoptotic cells were quantified by flow cytometry and expressed as the percentage of cells with apoptotic nuclei. Cytospins of stained cells were prepared and first 200 macrophages were counted for the presence of intracellular apoptotic bodies.
Killing of biofilm bacteria by neutrophils
An enriched population of neutrophils was obtained using lavaging the peritoneal cavity with PBS, 3 h after intraperitoneal injection of thioglycollate [31] . After lysis of erythrocytes in ACK lysis buffer (Invitrogen), white blood cells were washed once with PBS, suspended in RPMI, and purity of the neutrophil population determined by staining cytospins with Diff-Quick. Neutrophil purity was [90%. Mucoid PA was grown as a biofilm in 96 well plates, as described [32] . Planktonic bacteria were removed by washing once with sterile PBS and incubated with AZM (0-1,000 ng/ml) in the presence or absence of 1 9 10 5 neutrophils suspended in RPMI for 3 h at 37°C. Media from the wells was collected for the determination of density of planktonic bacteria, and biofilm mass was determined by crystal violet staining [32] .
Statistical analysis
Because sample sizes were not similar between groups (due to decreased survival in an experimental group infected with MPA and treated with PBS), results are expressed as geometric mean ± SEM. Data were analyzed using SigmaStat statistical software (Systat Software, San Jose, CA). ANOVA with Student's t test or Tukey-Kramer post hoc analysis was performed as appropriate to compare groups, and a P value \0.05 was considered significant.
Results

Survival of MPA-infected CF mice
To determine the effect of AZM on the survival of MPAinfected CF mice, mice were infected with MPA, treated with either saline or AZM daily starting at 24 h postinfection, and monitored for mortality until day 5. Around 4% of the infected animals died 24 h post-infection, i.e., before starting treatment. In MPA/saline group, mortality reached 54% by 5 days after infection (Fig. 1a) . The surviving mice in this group appeared very ill with ruffled skin, lethargy, and weight loss. In contrast, animals in MPA/AZM group showed improvement in their condition with time, and only 5% of the mice died. Animals treated with saline or alginate showed 100% survival.
Bacterial burden in the lungs
Mice infected with alginate alone or MPA were killed after 24 h to determine initial bacterial load. As expected, shaminfected mice did not show bacteria in their lungs, whereas MPA-infected mice showed 9.6 9 10 6 ± 1.3 9 10 6 CFU/ lung, indicating persistence of bacteria in these mice at day 1 post-infection. Animals in MPA/saline group showed a significantly higher bacterial load in the lungs at both 3 and 5 days than the MPA/AZM group (Fig. 1b) . In contrast, 9 out 11 mice in the AZM-treated group cleared bacteria from their lungs 5 days post-infection. These results indicate that AZM augments bacterial clearance. (Fig. 2a) . Saline treatment of MPA-infected mice did not affect neutrophil number at either 3 or 5 days postinfection. In contrast, AZM treatment decreased the number of neutrophils at both 3 and 5 days post-infection compared with MPA/saline group. The difference was statistically significant at 5 days post-infection. We also observed a small but significant increase in number of lymphocytes in the MPA/AZM group at both 3 and 5 days post-infection compared with the MPA/saline group.
MPO activity was significantly increased in mice infected with MPA compared with sham-infected animals 24 h post-infection (Fig. 2b) . Treatment of MPA-infected animals with saline did not significantly reduce lung MPO activity. In contrast, AZM treatment significantly reduced MPO activity at 3 days, and levels returned to normal by 5 days, consistent with neutrophil counts from the BAL fluid. Fig. 3 AZM treatment modulates cytokine expression in PA-infected mice. Supernatant of lung homogenates were used to determine cytokine levels by bioplex immune assay. Data represent geometric mean and SEM calculated from three independent experiments with a total of 9-11 mice per group (*different from sham infected mice; different from salinetreated groups, P B 0.05, ANOVA)
Cytokine analysis Proinflammatory cytokines were measured in lung homogenates by multiplex immune assay. Twenty-four hours after infection with MPA, mice showed significant increases in the proinflammatory cytokines IL-1b, IL-6, IL-17 and TNF-a, as well as the chemokines mouse growthrelated oncogene -a (KC) and monocyte chemoattractant protein (MCP)-1, compared with sham-infected control mice. Mice treated with AZM following MPA infection showed significantly lower levels of IL-1b, IL-6, IL-10, IL-17, TNF-a, MCP-1, and KC 3 and 5 days post-infection compared with mice treated with saline (Fig. 3) . In contrast, AZM-treated mice showed increased levels of IFN-c at both time points. These results are consistent with the decrease in neutrophil infiltration in the AZM-treated group.
Histology and detection of apoptotic cells
Histological evaluation of H&E stained sections revealed normal morphology in sham-infected mice (Fig. 4a) . Animals in the MPA/saline group at 5 days post-infection showed infiltration of neutrophils in airway lumen, peribronchiolar, and perivascular areas (Fig. 4b-d) , These mice also showed pneumonic consolidation in isolated areas of parenchyma ( Fig. 4e) with neutrophils being dominant cell type (Fig. 4f) . We observed very few activated macrophages in these mice (Fig. 4g) . In contrast, animals in MPA/AZM group showed mild inflammation in peribronchiolar and perivascular areas with mononuclear cells being predominant cell type (Fig. 5a, b) . Unlike animals in MPA/saline group, these mice did not show pneumonic consolidation in the parenchyma. However, we noticed many activated macrophages in the peribronchiolar, perivascular, and alveolar air spaces (Fig. 5c) . Some of the macrophages appear to have phagocytosed neutrophils within them.
We next examined the abundance of apoptotic cells and the association of apoptotic nuclei with macrophages to determine the effect of AZM on macrophage function. Animals in MPA/saline group showed a large number of apoptotic cells in the airway lumen (Fig. 6a) and peribronchiolar and perivascular areas (Fig. 6b) , with no obvious apoptotic bodies associated with macrophages (Fig. 6c) . On the other hand, animals in MPA/AZM group showed a few apoptotic cells in the peribronchiolar area (Fig. 6d) . Higher magnification revealed the presence of apoptotic bodies within the macrophages (Fig. 6d, e) . Quantitation of total apoptotic cell population in BAL by flow cytometry revealed significantly less apoptotic cells in AZM group than in saline group at both 3 and 5 days postinfection (Fig. 6f) . The number of BAL macrophages containing apoptotic bodies was then quantitated by microscopy (Fig. 6g) . Animals in MPA/saline group showed only 1-2% of macrophages positive for apoptotic bodies, whereas in MPA/AZM group 14 and 7.5% of macrophages were positive for apoptotic bodies at 3 and 5 days post-infection, respectively. These results imply that AZM improves the phagocytic uptake and clearance of apoptotic neutrophils by alveolar macrophages.
Killing of biofilm bacteria by neutrophils
Mucoid P. aeruginosa grown as a biofilm was incubated with neutrophils in the presence of AZM (0-1,000 ng/ml), and biofilm mass and density of planktonic bacteria determined (Fig. 7) . AZM by itself decreased the biofilm mass in a dose-dependent manner. The presence of neutrophils further reduced the mass of biofilm, particularly in the presence of higher doses of AZM. In the presence of AZM alone, the density of planktonic bacteria did not change significantly irrespective of the concentration of AZM used. In contrast, neutrophils decreased the number of planktonic bacteria significantly in the presence of AZM, compared with no AZM control and AZM alone. These results indicate that AZM disperses bacteria from the biofilm mass and renders them susceptible to killing by neutrophils.
Discussion
Pulmonary inflammation due to chronic infection with MPA is a major cause of morbidity and mortality in CF. Despite the availability of antibiotics, it is a challenge to eradicate PA infection in CF. This is probably because of an exaggerated host response to infection, combined with the immunomodulatory action of PA virulence factors and emergence of multidrug-resistant PA variants. This results in persistent neutrophilic inflammation which ultimately contributes to destruction of surrounding lung tissue. In this study, using a novel mouse model of endobronchial PA infection [25] , we show that low (sub-bactericidal) dose of AZM (20 mg/kg) significantly reduces inflammation and augments bacterial clearance in CF mice. This effect was associated with significant reduction in the lung cytokines In recent years, AZM has been used in the treatment of CF lung disease because of its anti-inflammatory and immunomodulatory actions. However, the precise mechanisms by which AZM improves pulmonary status in CF are unclear. In our previous studies, using an agar bead model of infection in normal mice, we demonstrated that subcutaneous administration of AZM once a day reduced inflammatory cell infiltration in the lungs without substantial changes in the bacterial load [20] . We also demonstrated that AZM attenuated neutrophil accumulation in the lungs partly by reducing the expression of neutrophil-attracting chemokines. Similarly, it has recently been demonstrated that AZM reduced both spontaneous and LPS-induced pulmonary inflammation in CF mice by inhibiting TNF-a and MIP-2 production [23] . To examine if AZM exerts a similar anti-inflammatory effect in MPAinfected CFTR knockout mice, we infected animals with MPA and treated with AZM subcutaneously starting from 1 day after infection. Treatment of CF mice with AZM prior to infection killed all the animals, indicating that these mice differ from normal mice in their innate defense mechanisms. However, treatment with AZM after the infection improved the survival rate by 95% compared with saline. As recently reported, we also observed a reduction in lung bacterial load in AZM-treated mice [24] . Because AZM does not have a bactericidal effect on gram-negative bacteria, we speculated that AZM aids the clearance of bacteria by indirect mechanisms. MPA often exists in biofilm matrix in the lungs, and are protected by phagocytes [2] [3] [4] . In this study, we demonstrated that AZM significantly decreased biofilm mass and increased the killing of planktonic bacteria by neutrophils ex vivo. This may explain the observed bacterial clearance in MPAinfected mice treated with AZM.
Reduced bacterial load in the lungs of AZM-treated mice was associated with significant reduction in neutrophil numbers and levels of the proinflammatory cytokines IL-1b, IL-6, IL-17 and TNF-a, as well as the chemokines KC and MCP-1. Since a neutrophilic inflammatory response is needed for clearance of PA from the lungs, it may seem paradoxical that AZM reduces both lung inflammation and bacterial load. This point is exemplified by the high mortality in mice pre-treated with AZM prior to PA infection (data not shown). However, once infection is established, the release of elastase from necrotic neutrophils causes further tissue damage and recruits more neutrophils to airways [6, 7] . Administration of AZM apparently increases survival in part by reducing lung inflammation. Of particular interest is IL-17, which is exclusively produced by Th 17 lymphocytes. IL-17 is increased during pulmonary exacerbations in CF, induces expression of neutrophil-attracting chemokines from airway epithelial cells, and plays a regulatory role in neutrophil recruitment in a murine model of P. aeruginosa infection [33, 34] . AZM has been demonstrated to effectively inhibit the IL-17-stimulated IL-8 production in human airway smooth muscle cells [35] . Thus, AZM may exert its anti-inflammatory effect by inhibiting IL-17 expression, which in turn attenuates airway epithelial cell chemokine expression. AZM also has direct inhibitory effects on airway epithelial cell IL-8 expression [36] .
We also found increased lung levels of IFN-c and decreased IL-10 in AZM-treated mice. IFN-c improves 1, 10, 50 , 100, 500, or 1,000 ng/ml) in the presence or absence of added neutrophils for 3 h. Biofilm mass (a) and density of planktonic bacteria (b) were determined by crystal violet staining and plating, respectively. Data represent mean and standard deviation calculated from three independent experiments carried out in quadruplicate (*different from AZM alone at respective concentrations; different from control group with no added AZM or neutrophils, P B 0.05, ANOVA) phagocytic killing of MPA protected in alginate biofilm by mononuclear cells [2] . P. aeruginosa induces a Th2-type response in mouse models of CF, and the observed shift to a Th1 response, including increased production of IFN-c and decreased IL-10, may decrease lung bacterial load and inflammation while improving survival [37, 38] . Consistent with this, CF patients with chronic infection with MPA show decreased levels of lung IFN-c, and growing evidence suggests that increasing IFN-c production may improve the prognosis in these patients [37, 39, 40] . In contrast to our findings, Sugiyama et al. [41] found that AZM increased IL-10 and decreased IFN-c production from bone marrow-derived dendritic cells and spleenderived T cells in response to LPS stimulation in vitro. This discrepancy may be due to dissimilar experimental conditions employed.
Azithromycin also directly promotes the phagocytic function of macrophages in vitro [16] . Macrophages play a pivotal role in clearing inflammatory cells that enter the lungs in response to infection and undergo apoptosis. Failed or reduced clearance of these apoptotic cells results in accumulation of inflammatory cells that eventually undergo necrosis and release tissue-damaging proteases [42] . This scenario is frequently observed in CF lungs [43, 44] . Indeed, it was recently demonstrated that low-dose AZM improved phagocytic capacity of alveolar macrophages in vitro and in patients with COPD [16, 45] . In the present study, we observed that, at 3 and 5 days postinfection, mice treated with AZM showed fewer lung neutrophils and an overall reduction in the abundance of apoptotic cells compared with mice treated with PBS. Microscopic examination revealed a significant increase in number of macrophages with intracellular apoptotic bodies. These results imply that AZM promote clearance of apoptotic cells by improving the phagocytic function of macrophages.
In summary, we have demonstrated that AZM effectively reduces PA-induced inflammation by reducing bacterial load, decreasing elaboration of proinflammatory cytokines, increasing IFN-c and improving clearance of apoptotic cells by macrophages.
